研究论文
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
Qi Zhang, Qihan Fu, Yinan Shen, Wanyue Cao, Gaowei Jin, Yize Zhang, Jiangchao Wu, Cao Chen 等 35 位
First Affiliated Hospital Zhejiang University Zhejiang University AstraZeneca (United Kingdom) Shanghai AbelZeta Ltd. (China)
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
摘要 · 节选
暂未获取摘要。可打开原文或 PDF，后续可基于全文生成更完整的速读。
逐年被引趋势
210
226
关键指标
2
被引次数 · OpenAlex
7.06
领域内被引倍数
同类平均 = 1
同类平均 = 1
前 3%
引用位次
同领域 · 同年份 · 同类型
同领域 · 同年份 · 同类型
29
参考文献
Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。
AI 辅助阅读
依据：文献信息
论文问答
当前基于文献信息回答
可就本文提问；依据不足时会说明。
学术脉络
学科主题
生物医学CAR-T cell therapy research
Cancer Immunotherapy and Biomarkers · Immunotherapy and Immune Responses
参考文献 29
Sorafenib in Advanced Hepatocellular Carcinoma
被引 13,116Josep Maria Llovet, Sergio Ricci, Vincenzo Mazzaferro · New England Journal of Medicine · 2008
Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases
被引 214Yasuhiro Shirai, Sumio Kawata, Shinji Tamura · Cancer · 1994
Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients
被引 69Ning Su, Bin Chen, Na Huang · Molecular Biology Reports · 2011
此处列出前 3 条
引用本文 2
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
被引 0Tim F. Greten, Mitchell Ho · Nature Reviews Clinical Oncology · 2026
Engineering controllable CAR T-cell therapies: from binary safety switches to programmable immunity
被引 0Sergei Smirnov, Yuriy Zaritskey, Galina Salogub · Frontiers in Immunology · 2026
按被引量排序，此处列出前 3 条